Adoptive immunotherapy for recurrent CML after BMT.
Three patients with CML who relapsed after transplantation with T-depleted BM from their HLA-identical siblings were treated with transfusions of donor peripheral blood mononuclear cells, in combination with (short) IFN alpha 2 therapy. CML was successfully controlled as shown by the complete disappearance of Philadelphia-positive metaphases within 90 days of treatment. This treatment appears to be very effective as neither bcr-abl transcripts nor markers specific for hematological cells of recipient origin could be detected by very sensitive PCR techniques. Two patients treated in chronic phase are without evidence of disease 300 and 360 days after treatment. The third patient, treated in accelerated phase, died with BM aplasia, 39 days following PBMC infusions. Failure to detect residual donor-derived granulocytes, as was the case in this patient prior to initiating adoptive immunotherapy, may indicate loss of donor-derived BM activity. This may help predict and possibly prevent the occurrence of life-threatening aplasia after successful clearance of malignant hematopoiesis.
Helg
C
C
Department of Medicine, University Hospital, Geneva, Switzerland.
Roux
E
E
Beris
P
P
Cabrol
C
C
Wacker
P
P
Darbellay
R
R
Wyss
M
M
Jeannet
M
M
Chapuis
B
B
Roosnek
E
E
D000208:Acute Disease; D000328:Adult; D016026:Bone Marrow Transplantation; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D016219:Immunotherapy, Adoptive; D007262:Infusions, Intravenous; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000601:surgery*; D007963:Leukocytes, Mononuclear; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D018183:Transplantation Chimera
D016898:Interferon-alpha